来源：金融界 最近三个交易日，20日-22日，赛诺医疗分别获融资买入3.78亿元、3.31亿元、3.16亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 8月22日，沪深两融数据显示，赛诺医疗获融资买入额3.16亿元，居两市第70位，当日融资偿还额3.29亿 元，净卖出1269.64万元。 ...

Core Viewpoint - The article highlights that Sino Medical has shown significant financial recovery and potential for growth, particularly with its drug-eluting stent receiving FDA conditional approval, marking a pivotal moment for domestic medical devices in the U.S. market [2][33]. Financial Performance - Revenue has recovered to 240 million yuan, an increase of 12.53% year-on-year [5]. - Net profit reached 13.84 million yuan, a year-on-year increase of 296.54% [5]. - The operating cash flow net amount was 52.45 million yuan, up 303.38% year-on-year, exceeding net profit [11]. - Gross margin remained stable at 71%, indicating that price pressures have been absorbed by structural and cost adjustments [11]. Business Progress - The coronary intervention business generated 187 million yuan, a growth of 17.40%, accounting for 78% of total revenue [6]. - The company has expanded its international market presence, with products approved in countries like Argentina and Ecuador [14]. - The FDA conditional approval for the new drug-eluting stent system is a significant milestone, potentially opening the U.S. market for Sino Medical [14]. R&D and Innovation - R&D expenses were 77.8 million yuan, accounting for 32.36% of revenue, which is significantly higher than the industry average [21]. - The company has a robust pipeline covering three major high-barrier areas: coronary, neuro, and structural heart disease [22]. - The introduction of AI in production processes aims to enhance product consistency and stability, crucial for future overseas supply [22]. Market Position and Strategy - Sino Medical is positioned as a resilient player in a challenging environment, focusing on both immediate recovery and long-term growth through innovation [10][20]. - The company is not solely reliant on one business line but is diversifying its offerings to navigate competitive pressures [17]. - The potential for FDA approval and successful market penetration in the U.S. could redefine Sino Medical's industry standing [27][32].

本次财报公布的各项数据指标表现尚佳。其中，毛利率63.64%，同比增7.51%，净利率5.48%，同比增 6179.82%，销售费用、管理费用、财务费用总计8439.93万元，三费占营收比35.1%，同比减8.04%，每 股净资产2.15元，同比增2.42%，每股经营性现金流0.13元，同比增300.87%，每股收益0.03元，同比增 200.0% 据证券之星公开数据整理，近期赛诺医疗（688108）发布2025年中报。截至本报告期末，公司营业总收 入2.4亿元，同比上升12.53%，归母净利润1384.16万元，同比上升296.54%。按单季度数据看，第二季 度营业总收入1.4亿元，同比上升13.86%，第二季度归母净利润1087.23万元，同比上升110.56%。本报 告期赛诺医疗盈利能力上升，毛利率同比增幅7.51%，净利率同比增幅19.72%。 | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 2.14亿 | 2.4亿 | 12.53% | | 归母浄利润（元） | 349.06万 | 1384.16万 | ...

Core Viewpoint - The stock of Sino Medical Science Technology Co., Ltd. experienced a significant decline, with a cumulative drop of 30% over three consecutive trading days, indicating abnormal trading fluctuations [1][7]. Group 1: Stock Trading Fluctuations - The company's stock closed at 32.70 yuan per share as of August 22, 2025, with recent price volatility exceeding that of most peers and the Shanghai Composite Index [3][9]. - The rolling price-to-earnings ratio of the company is reported at 2318.77, significantly deviating from the industry average of 34.84 [3][9]. - The trading turnover rates for August 20, 21, and 22, 2025, were 16.56%, 19.01%, and 14.54%, respectively, indicating a notable increase compared to previous levels [3][9]. Group 2: Company Announcements and Developments - The company disclosed that it received conditional approval from the FDA for its new drug-eluting stent system on July 22, 2025, and announced the breakthrough medical device certification for its subsidiary's products on August 7, 2025 [2][8]. - The COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter received FDA breakthrough device designation, which provides expedited review and support for product development [4][10]. - The blood flow-directed mesh stent system, AUCURA, obtained domestic medical device registration in May 2025 and was selected for a procurement project in Guangdong province, set to commence on September 1, 2025 [5][12]. Group 3: Financial Performance - The company reported a net profit of -39.63 million yuan for 2023 and 1.38 million yuan for the first half of 2025, indicating a recovery from previous losses [6][13]. - The financial results highlight the company's ongoing efforts to stabilize and improve its profitability amidst market fluctuations [6][13].

Group 1 - The stock price of Sino Medical as of August 22, 2025, is 32.70 yuan, down by 1.52 yuan, representing a decline of 4.44% from the previous trading day [1] - The opening price for the day was 33.50 yuan, with a highest price of 34.56 yuan and a lowest price of 32.41 yuan, resulting in a trading volume of 605,087 lots and a total transaction amount of 2.01 billion yuan [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of interventional medical devices, with products covering cardiovascular and cerebrovascular fields [1] Group 2 - On August 22, 2025, the net outflow of main funds from Sino Medical was 208.97 million yuan, accounting for 1.54% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 1.31 billion yuan, representing 9.64% of the circulating market value [1]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-038 赛诺医疗科学技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）股票交 易于 2025 年 8 月 20 日、2025 年 8 月 21 日、2025 年 8 月 22 日连续 3 个交易日内日收 盘价格跌幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所 科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 ? 经公司自查，公司于 2025 年 7 月 22 日发布了《赛诺医疗关于公司新型药物洗 脱支架系统获得美国 FDA 附条件批准的自愿性披露公告》（公告编号：2025-029），于 破性医疗器械认证的自愿性披露公告》（公告编号：2025-031），于 2025 年 8 月 22 日 发布了《赛诺医疗科学技术股份有限公司 2025 年半年度报告》，除上述已披露信息外， 截至目前，公司未发 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-038 赛诺医疗科学技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）股票交 易于 2025 年 8 月 20 日、2025 年 8 月 21 日、2025 年 8 月 22 日连续 3 个交易日内日收 盘价格跌幅偏离值累计达到 30%，根据《上海证券交易所交易规则》《上海证券交易所 科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 经公司自查，公司于 2025 年 7 月 22 日发布了《赛诺医疗关于公司新型药物洗 脱支架系统获得美国 FDA 附条件批准的自愿性披露公告》（公告编号：2025-029），于 2025 年 8 月 7 日发布了《赛诺医疗科学技术股份有限公司关于子公司产品获得 FDA 突 破性医疗器械认证的自愿性披露公告》（公告编号：2025-031），于 2025 年 8 月 22 日 发布了《赛诺医疗 ...

截至2025年6月30日，赛诺医疗实现营业总收入2.40亿元，同比增长12.53%，实现归属净利润1384.16万 元，同比增长296.54%。流动比率、速动比率分别为2.395、1.917，资产负债率为29.39%。 来源：金融界 8月22日收盘，赛诺医疗当日下跌4.44%，成交额20.10亿元，换手率14.54%。从区间来看，该股近3个交 易日累计下跌19.1%。 资金流向方面，今日主力资金净流出20897.22万元，占成交比10.4%，其中超大单净流出18702.38万 元，占成交比9.31%。 赛诺医疗主营业务：公司专注于高端介入医疗器械研发、生产、销售,产品管线涵盖心血管、脑血管、 结构性心脏病等介入治疗重点领域。公司自主研发设计的、拥有国际知识产权的BuMA生物降解药物涂 层冠脉支架系统是公司的核心产品。 ...

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

Market Overview - The net inflow of main funds in the Shanghai and Shenzhen markets reached 25.419 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 6.497 billion yuan [1] - A total of 278 stocks experienced net inflows, while 309 stocks faced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 470 stocks rose, with 6 stocks hitting the daily limit, including Shengmei Shanghai and Yuntian Lefe [1] - 112 stocks declined in value [1] Key Stocks with Significant Fund Inflows - The top three stocks with the highest net inflows were: - SMIC (中芯国际) with a net inflow of 2.579 billion yuan, ranking first [2] - Haiguang Information (海光信息) with a net inflow of 1.459 billion yuan [2] - Lanke Technology (澜起科技) with a net inflow of 481.64 million yuan [2] Stocks with Continuous Fund Inflows - A total of 56 stocks have seen continuous net inflows for more than three trading days, with Huahai Qingke (华海清科) leading at 10 consecutive days [2] - The stocks with the most extended net outflows included Fudan Zhangjiang (复旦张江) with 15 consecutive days of outflows [2] Fund Inflow Rankings - The top stocks by net inflow and their respective data include: - SMIC (中芯国际): 2.579 billion yuan, 12.69% inflow rate, 14.19% increase [2] - Haiguang Information (海光信息): 1.459 billion yuan, 10.97% inflow rate, 20.00% increase [2] - Lanke Technology (澜起科技): 481.64 million yuan, 7.00% inflow rate, 8.70% increase [2] Summary of Fund Outflows - The stock with the highest net outflow was Yingshi Innovation (影石创新) with a net outflow of 332 million yuan and a decline of 4.34% [1] - Other notable outflows included Sainuo Medical (赛诺医疗) and Tiebian Heavy Industry (铁建重工) with outflows of 223 million yuan and 143 million yuan, respectively [1]